Investor Relations

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Nov 14, 2024
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
NEW YORK , Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other
Corporate Presentation

SEC Filings

Form Description Filing date View
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

 View HTML
0001140361-24-050096.pdf
0001140361-24-050096.rtf
0001140361-24-050096.xls
3

Initial filing by director officer or owner of more than ten percent

 View HTML
0000950170-24-134507.pdf
0000950170-24-134507.rtf
0000950170-24-134507.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000950170-24-134524.pdf
0000950170-24-134524.rtf
0000950170-24-134524.xls
PRE 14A

A preliminary proxy statement providing notification matters to be brought to a vote

 View HTML
0001140361-24-048693.pdf
0001140361-24-048693.rtf
0001140361-24-048693.xls

Data provided by Kaleidoscope.